Table 3 Feasibility outcome: compliance in TXA trial
|  | All (N = 100) | TXA (N = 49) | Placebo (N = 51) |
|---|---|---|---|
Patients who received both doses of study drug, n (%; 95% CI) | 89 (89.0; 81.2–94.4) | 45 (91.8; 80.4–97.7) | 44 (86.3; 73.7–94.3) |
Patients who received only one dose of study drug, n (%; 95% CI) | 2 (2.0; 0.2–7.0) | 1 (2.0; <  0.1–10.8) | 1 (2.0; <  0.1–10.4) |
Patients who received no dose of study drug, n (%; 95% CI) | 9 (9.0; 4.2–16.4) | 3 (6.1; 1.3–16.9) | 6 (11.8; 4.4–23.9) |